EGFR and non-small cell lung carcinoma: Second, we do not have immune contexture, the amount of immune cell infiltration, in tumors, which can more precisely reflect the immune response in tumor microenvironment.[23] Further studies are required to determine whether add-on immunotherapy or anti-angiogenesis agents, in addition to first line EGFR-TKIs, could prolong survival in NSCLC patients, especially in those with low LMR.